Serum antibody against helicobacter pylori flaa and risk of gastric cancer

Helicobacter

Volumn 19, Issue 1, 2014, Pages 9-16

  Tian, Wenjing ^a   Jia, Yunhe ^a   Yuan, Kexin ^a   Huang, Lina ^a   Nadolny, Christina ^b   Dong, Xiaoqun ^b   Ren, Xiyun ^a   Liu, Jingjing ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Case control study; Gastric cancer; H. pylori FlaA protein; Serum antibody

Indexed keywords

ANTIBODY; BACTERIAL PROTEIN; BIOLOGICAL MARKER; FLAGELLIN; FLAGELLIN A ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ALCOHOL CONSUMPTION; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER RISK; CANCER STAGING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; EDUCATIONAL STATUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR CLONING; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SMOKING; STOMACH CANCER;

CASE-CONTROL STUDY; GASTRIC CANCER; H. PYLORI FLAA PROTEIN; SERUM ANTIBODY;

AGED; ANTIBODIES, BACTERIAL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLAGELLIN; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890885816     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12095     Document Type: Article

References (49)

1. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 2009;472:467-77.
2. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: a summary review to 2007. Recent Results Cancer Res 2009;181:231-51.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
4. Bertuccio P, Chatenoud L, Levi F, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer 2009;125:666-73.
5. Kikuchi S, Katada N, Sakuramoto S, et al. Survival after surgical treatment of early gastric cancer: surgical techniques and long-term survival. Langenbecks Arch Surg 2004;389:69-74.
6. Msika S, Benhamiche AM, Jouve JL, et al. Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer 2000;36:390-6.
7. Khan MI, Baqai MT, Bukhari M, Hashmi RI. Gastric carcinoma: 5 years survival after gastric surgery. J Pak Med Assoc 2005;55:158-60.
8. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000;26:243-55.
9. Warren J, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-5.
10. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
11. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
12. de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am 2013;42:219-40.
13. Cavaleiro-Pinto M, Peleteiro B, Lunet N, Barros H. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control 2011;22:375-87.
14. Kikuchi S, Crabtree JE, Forman D, Kurosawa M. Association between infections with CagA-positive or -negative strains of Helicobacter pylori and risk for gastric cancer in young adults. Research Group on Prevention of Gastric Carcinoma Among Young Adults. Am J Gastroenterol 1999;94:3455-9.
15. Lahner E, Bernardini G, Santucci A, Annibale B. Helicobacter pylori immunoproteomics in gastric cancer and gastritis of the carcinoma phenotype. Expert Rev Proteomics 2010;7:239-48.
16. Delahay RM, Rugge M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2012;17(Suppl. 1):9-15.
17. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
18. Shiota S, Matsunari O, Watada M, Yamaoka Y. Serum Helicobacter pylori CagA antibody as a biomarker for gastric cancer in east-Asian countries. Future Microbiol 2010;5:1885-93.
19. Ford AC. Chemoprevention for gastric cancer. Best Pract Res Clin Gastroenterol 2011;25:581-92.
20. Asaka M, Kato M, Graham DY. Prevention of gastric cancer by Helicobacter pylori eradication. Intern Med 2010;49:633-6.
21. Fuccio L, Zagari RM, Minardi ME, Bazzoli F. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007;25:133-41.
22. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94.
23. Peek RM Jr, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol 2006;208:233-48.
24. Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010;23:713-39.
25. Suerbaum S, Josenhans C, Labigne A. Cloning and genetic characterization of the Helicobacter pylori and Helicobacter mustelae flaB flagellin genes and construction of H. pylori flaA- and flaB-negative mutants by electroporation-mediated allelic exchange. J Bacteriol 1993;175:3278-88.
26. Asakura H, Churin Y, Bauer B, et al. Helicobacter pylori HP0518 affects flagellin glycosylation to alter bacterial motility. Mol Microbiol 2010;78:1130-44.
27. Zhou MG, Wang XF, Hu JP, et al. Geographical distribution of cancer mortality in China, 2004-2005. Chinese journal of preventive medicine 2010;44:303-8.
28. Yan J, Liang SH, Mao YF, et al. Construction of expression systems for flaA and flaB genes of Helicobacter pylori and determination of immunoreactivity and antigenicity of recombinant proteins. World J Gastroenterol 2003;9:2240-50.
29. Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997;388:539-47.
30. Alm RA, Ling LS, Moir DT, et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 1999;397:176-80.
31. Oh JD, Kling-Backhed H, Giannakis M, et al. The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: evolution during disease progression. Proc Natl Acad Sci U S A 2006;103:9999-10004.
32. Sutton P, Chionh YT. Why can't we make an effective vaccine against Helicobacter pylori? Expert Rev Vaccines 2013;12:433-41.
33. Lahner E, Bernardini G, Santucci A, Annibale B. Helicobacter pylori immunoproteomics in gastric cancer and gastritis of the carcinoma phenotype. Expert Rev Proteomics 2010;7:239-48.
34. Shiota S, Suzuki R, Yamaoka Y. The significance of virulence factors in Helicobacter pylori. J Dig Dis 2013;14:341-9.
35. Takahashi A, Shiota S, Matsunari O, et al. Intact long-type dupA as a marker for gastroduodenal diseases in Okinawan subpopulation, Japan. Helicobacter 2013;18:66-72.
36. Gao L, Weck MN, Michel A, et al. Association between chronic atrophic gastritis and serum antibodies to 15 Helicobacter pylori proteins measured by multiplex serology. Cancer Res 2009;69:2973-80.
37. van Amsterdam K, van der Ende A. Helicobacter pylori HP1034 (ylxH) is required for motility. Helicobacter 2004;9:387-95.
38. Franco AT, Friedman DB, Nagy TA, et al. Delineation of a carcinogenic Helicobacter pylori proteome. Mol Cell Proteomics 2009;8:1947-58.
39. Annibale B, Lahner E, Santucci A, et al. CagA and VacA are immunoblot markers of past Helicobacter pylori infection in atrophic body gastritis. Helicobacter 2007;12:23-30.
40. Ekstrom AM, Held M, Hansson LE, et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001;121:784-91.
41. Sorberg M, Engstrand L, Strom M, et al. The diagnostic value of enzyme immunoassay and immunoblot in monitoring eradication of Helicobacter pylori. Scand J Infect Dis 1997;29:147-51.
42. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-53.
43. Kamangar F, Dawsey SM, Blaser MJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 2006;98:1445-52.
44. Zhang DH, Zhou LY, Lin SR, et al. Recent changes in the prevalence of Helicobacter pylori infection among children and adults in high- or low-incidence regions of gastric cancer in China. Chin Med J (Engl) 2009;122:1759-63.
45. Lee WJ, Lin JT, Lee WC, et al. Clinicopathologic characteristics of Helicobacter pyloric seropositive gastric adenocarcinomas. J Clin Gastroenterol 1995;21:203-7.
46. Gao L, Michel A, Weck MN, et al. Helicobacter pylori infection and gastric cancer risk: evaluation of H. pylori proteins determined by novel multiplex serology. Cancer Res 2009;69:6164-70.
47. Syrios J, Sougioultzis S, Xynos ID, et al. Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter pylori infection. BMC Cancer 2012;12:264.
48. Hur H, Lee SR, Xuan Y, et al. The Effects of Helicobacter pylori on the prognosis of patients with curatively resected gastric cancers in a population with high infection rate. J Korean Surg Soc 2012;83:203-11.
49. Gonzalez CA, Megraud F, Buissonniere A, et al. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. Ann Oncol 2012;23:1320-4.